Anavex Life Sciences Corp (AVXL)

[Doktornolittle]

I like the idea of genetic patient targeting. It increases the chance of a trial success, and it is more fair to patients and competing therapies.

A year or so ago, Biogen shares/cap dropped $20B on news of their P3 Alz treatment not doing well (as I recall). The market for Alz alone is absolutely enormous, so finding a legitimate slice of that pie would be a wonderful thing for patients and investors alike.

I'm not saying this approach is not a smoke screen. It could be, but I am saying that it makes total sense and may be real. Back when I paid a lot of attention to oncology drugs/therapies, and spent a lot of time on these message boards, I pushed the ethics of target patient populations. There the subject became very complex as cancers mutate from one type to another, etc.. Maybe such will turn out to be messy here as well, and maybe not. If they came up with a significant, apriori identifiable population of Alz patients that benefits highly from 2-73 or 2-73 plus then that will be huge!!!!!!!!! And right now there is reason to hope that is exactly what is about to be announced next week.